Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Gastroenterology - 1 Jan 2004

Peters Marion G, Hann Hw H w, Martin Paul, Heathcote E Jenny, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df D f, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart Carol L

Abstract excerpt

BACKGROUND AND AIMS: Adefovir dipivoxil possesses potent in vitro and in vivo antiviral activity in wild-type hepatitis B. This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in patients with chronic hepatitis B with compensated liver disease and lamivudine-resistant hepatitis B virus (HBV). METHODS: Fifty-nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 14699491
DOI: 10.1053/j.gastro.2003.10.051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.PMID 14699491Read ↗

Treatment of patients with chronic hepatitis B with adefovir dipivoxil.Semantic proximity Read ↗

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.Semantic proximity Read ↗

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.Semantic proximity Read ↗

Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.Semantic proximity Read ↗

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.Semantic proximity Read ↗

Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.Semantic proximity Read ↗

Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B.Semantic proximity Read ↗

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.Semantic proximity Read ↗

Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.